0 CHECKOUT

PRODUCT FILTERS

REGION

50
14
14
12
11

COUNTRY

7
6
4
3
3

CATEGORIES

  • 48
  • 28
  • 16
  • 13
  • 12
  • 9
  • 7
  • 7
  • 7
  • 6
  • 5
  • 5
  • 4
  • 3
  • 3
  • 3
  • 2
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
SHOW ALL

PRICE

45
51
70
156

PUBLISHED

0
12
44
156

PRODUCT TYPE

110
42
4

Search for: "AstraZeneca: Performance, Products, Pipeline and Potential"

156 Products

AstraZeneca PLC (AZN) - Financial and Strategic SWOT Analysis Review

AstraZeneca PLC (AZN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by The...

Published:  April 2015
Price:  From

Pharmaceutical Industry in China - Cutting-Edge Analysis of Multinational and Chinese Pharma Companies, Industry Trends, Environment, Regulation, Market Drivers, Restraints, Opportunities & Challenges

“Pharmaceutical Industry China – Cutting-Edge Analysis of Multinational and Chinese Biopharma Companies, Industry Trends, Environment, Regulation, Market Drivers, Restraints, Opportunities & Challenges”...

Published:  March 2014
Price:  From

Diabetes - KOL Insight and Consensus Outlook Modules

The medium term: battle lines are drawn The fundamental drivers of the global diabetes market are strong and continue to fuel growth. Rising levels of obesity and disease prevalence in both established...

Published:  September 2013
Price:  From

Pharmaceutical Products of the Future: 50-Company Biopharma and Traditional Pipeline Analysis to 2016

What Will the Pharma Industry Look Like in 5 Years? There are an estimated 724 projects in development from the top 50 pharmaceutical companies.  Together, they have the potential to add billions...

Published:  August 2012
Price:  From

Pharmaceutical Industry in China to 2020: An In Depth Analysis of Multinational and Chinese Biopharma Companies, Industry Trends, Environment, Regulation, Market Drivers, Restraints, Opportunities & Challenges

“Pharmaceutical Industry in China to 2020: An In Depth Analysis of Multinational and Chinese Biopharma Companies, Industry Trends, Environment, Regulation, Market Drivers, Restraints, Opportunities...

Published:  July 2015
Price:  From

Rare Diseases: The Pharmaceutical Landscape and Opportunity Areas

The service oriented and dynamic nature of the healthcare industry has led to the discovery of a plethora of treatment options for a wide range of ailments.However, there are certain diseases, termed...

Published:  March 2015
Price:  From

Pharmaceutical Products of the Future: 50-Company Pipeline Analysis to 2015

What Will The Pharmaceutical Market Look Like in the Next Five Years? In this report, Kalorama has analyzed the late stage R&D pipeline of the 50 top companies in pharmaceuticals -- the companies...

Published:  July 2010
Price:  From

DPP IV Inhibitors - Global Strategic Business Report

This report analyzes the worldwide markets for DPP-IV Inhibitors in US$ Million by the following drugs – Sitagliptin, Vildagliptin, Saxagliptin, and Other DPP-IV Inhibitors (including Linagliptin and...

Published:  September 2011
Price:  From

Asthma Therapeutics Market to 2019 - Breakthrough Biologics to Enhance Treatment of Severe Asthma and Drive Market Growth

The asthma market is forecast to grow marginally over the forecast period across the leading eight developed nations, from $16 6 billion in 2012 to a projected value of $21 6 billion in 2019 This growth...

Published:  October 2013
Price:  From

Non-Tyrosine Kinase Inhibitors in Oncology, 2015 - 2025

Over decades, the oncology market has been led by surgery, chemotherapy and radiotherapy. The non-specificity of chemotherapy/radiotherapy and limitations of surgery has expanded the focus of many pharmaceutical...

Published:  April 2015
Price:  From

Lung Cancer Therapeutics Market Outlook and Pipeline Analysis

With over 50% of all non-small cell lung cancer (NSCLC) patients diagnosed at the advanced stages of the disease, and 95% of all small-cell lung cancer (SCLC) patients unsuitable for surgical resection,...

Published:  November 2009
Price:  From

Global Biopharma Outlook 2012 - Major US and EU Pharma

Global Biopharma Outlook 2012 –Major US and EU Pharma Unarguably 2011 was one of the very good years for the global Pharma industry as the USFDA approved a trend setting 39 new drugs, which is way ahead...

Published:  January 2012
Price:  From

World Anti-Inflammatory Therapeutics - Market Opportunities and Forecasts, 2014 - 2020

Inflammation is triggered by the defense system of the body in response to harmful stimuli, damaged cells, irritants and microorganisms. Inflammation is the mechanism of innate immunity, which seeks...

Published:  June 2015
Price:  From

Global Biopharma Outlook 2011: Major US and EU

The year 2011 and 2012 will be a bonanza for generic companies, as large innovator companies will lose patent exclusivity on prescription drugs worth over $70b in sales It is imperative to understand...

Published:  February 2011
Price:  From

Ovarian Cancer Therapeutics in Asia-Pacific Markets to 2020 - Off-patent Chemo-regimens to Retain Dominance Despite New Launches

This report provides estimates of the market size for 2013, along with forecasts until 2020 for the Asia-Pacific markets of India, China, Australia and Japan. It also covers disease epidemiology, treatment...

Published:  January 2015
Price:  From

Global Pharmaceutical & Biotechnology Outlook 2014: Major US and EU

Strategy Diversification Divested: Productivity measurements, divestment of non-core assets resulting in healthy cash position This will accelerate the next wave of targeted acquisition In recent years...

Published:  January 2014
Price:  From
Global Pharmaceutical & Biotechnology Outlook 2014: Major US and EU Global Pharmaceutical & Biotechnology Outlook 2014: Major US and EU - Product Thumbnail Image

Global Pharma US & EU Outlook 2015: First -In-Class Innovations and Cost Optimization Plays Major Role In Shaping Up Business for Large Cap Pharmaceutical Companies

Strategy Diversification Divested: Productivity measurements, Divestment of non-core assets resulting in healthy Cash position- Will accelerate Next wave of targeted acquisition In the recent years...

Published:  January 2015
Price:  From

Immune Checkpoint Inhibitors Market (2nd edition), 2015-2025

Cancer is known to be one of the leading causes of death worldwide. The field of oncology is vast and comprises several indications, including some rare / orphan forms. Although oncology continues to...

Published:  July 2015
Price:  From

Chronic Obstructive Pulmonary Disease (COPD) Market to 2019 - Highly-Priced New Combination Products Forecast to Capture Significant Market Share and Drive Growth

The global COPD market is estimated to currently be worth $11 3 billion, and is forecast to reach a value of $15 6 billion by 2019 Much of this growth will be fuelled by a high number of new, more efficacious...

Published:  June 2013
Price:  From

Astra Tech AB - Strategic SWOT Analysis Review

Astra Tech AB - Strategic SWOT Analysis Review Summary Astra Tech AB (Astra Tech) is a medical device company engaged in the research, development, manufacture and marketing of dental implants and...

Published:  August 2011
Price:  From
Loading Indicator

Our Clients

  • Procter & Gamble Co.
  • Western Union Company
  • Volvo Car Corporation
  • Morgan Stanley
  • SAP SE
  • LG Corporation
  • Roche Diagnostics Ltd.